Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 233-240

  Grunberg, Steven M ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Antiemetic; Corticosteroid; Dexamethasone; Methylprednisolone

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CANNABINOID DERIVATIVE; CARMUSTINE; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOMPERIDONE; EPIRUBICIN; GABAPENTIN; GRANISETRON; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; OLANZAPINE; ONDANSETRON; PALONOSETRON; PLACEBO; RAMOSETRON; SEROTONIN ANTAGONIST; STREPTOZOCIN; TACHYKININ RECEPTOR ANTAGONIST; TROPISETRON; UNINDEXED DRUG;

ACNE; AGITATION; ANTICIPATORY NAUSEA AND VOMITING; ANTIEMETIC ACTIVITY; BEHAVIOR THERAPY; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CATARACT; CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS; DEPRESSION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HICCUP; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INCREASED APPETITE; INFECTION RISK; INSOMNIA; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; METABOLISM; MONOTHERAPY; MYOPATHY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THRUSH; WEIGHT GAIN; WOUND HEALING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; GLUCOCORTICOIDS; HUMANS; MAXIMUM TOLERATED DOSE; NAUSEA; NEOPLASMS; PRACTICE GUIDELINES; VOMITING;

EID: 33847262912     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl347     Document Type: Review

References (54)

1. Schnell FM. Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. Oncologist 2003; 8: 187-198.
2. Sun CC, Bodurka DC, Weaver CB et al. Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. Support Care Cancer 2005; 13: 219-227.
3. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005; 6: 93-102.
4. Glaus A, Knipping C, Morant R et al. Chemotherapy-induced nausea and vomiting in routine practice: A European perspective. Support Care Cancer 2004; 12: 708-715.
5. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109.
6. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947.
7. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: Current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005; 41: 199-205.
8. Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - An update. Support Care Cancer 2005; 13: 80-84.
9. Lindley CM, Hirsch JD, O'Neill CV et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1: 331-340.
10. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 2004; 12: 550-554.
11. Herrstedt J, Koeller JM, Roila F et al. Acute emesis: Moderately emetogenic chemotherapy. Support Care Cancer 2005; 13: 97-103.
12. Mantovani G, Maccio A, Esu S, Lai P. Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect. Eur J Cancer 1996; 32A: 1983-1985.
13. Minami M, Endo T, Hamaue N, Hirafuji M. Serotonin and anticancer drug-induced emesis. Yakugaku Zasshi 2004; 124: 491-507.
14. Tanihata S, Oda S, Nakai S, Uchiyama T. Antiemetic effect of dexamethasone on cisplatin-induced early and delayed emesis in the pigeon. Eur J Pharmacol 2004; 484: 311-321.
15. Ho CM, Ho ST, Wang JJ et al. Dexamethasone has a central antiemetic mechanism in decerebrated cats. Anesth Analg 2004; 99: 734-739.
16. 3A receptor expressed in Xenopus oocytes. Anesthesiology 2004; 101: 660-665.
17. Gez E, Sulkes A, Ochayon L et al. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: A randomized crossover blind study. J Chemother 1989; 1: 365-368.
18. Campora E, Chiara S, Bruzzi P et al. The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: A randomized trial. Tumori 1985; 71: 459-462.
19. Basurto C, Roila F, Bracarda S et al. A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents. Am J Clin Oncol 1988; 11: 594-596.
20. Pieters RC, Vermorken JB, Gall HE et al. A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg with 500 mg methylprednisolone succinate (Solu-Medrol) as a single intravenous dose in patients treated with noncisplatin chemotherapy. Oncology 1993; 50: 316-322.
21. Zaglama NE, Rosenblum SL, Sartiano GP et al. Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy. Oncology 1986; 43: 27-32.
22. Goedhals L, Heron JF, Kleisbauer JP et al. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study. Ann Oncol 1998; 9: 661-666.
23. Ibrahim EM, Al-Idrissi HY, Ibrahim A et al. Antiemetic efficacy of high-dose dexamethasone: Randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. Eur J Cancer Clin Oncol 1986; 22: 283-288.
24. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 2000; 18: 3409-3422.
25. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Saf 1993; 9: 410-428.
26. Roila F, Tonato M, Basurto C et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: A randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987; 5: 141-149.
27. Clerico M, Bertetto O, Morandini MP et al. Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design. Tumori 1993; 79: 119-122.
28. Gonzalez Baron M, Chacon JI, Garcia-Giron C et al. Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam. Acta Oncol 1991; 30: 623-627.
29. Roila F, Basurto C, Bracarda S et al. Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis. Eur J Cancer 1991; 27: 119-121.
30. Roila F, Bracarda S, Basurto C et al. Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients. Am J Clin Oncol 1992; 15: 112-114.
31. Gebbia V, Testa A, Valenza R et al. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Cancer 1995; 76: 1821-1828.
32. Fauser AA, Pizzocaro G, Schueller J et al. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 2000; 8: 49-54.
33. Villalon A, Chan V. Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis. Support Care Cancer 2004; 12: 58-63.
34. Sorbe BG, Hogberg T, Glimelius B et al. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: The Nordic experience. The Nordic Antiemetic Trial Group. Anticancer Drugs 1995; 6 (Suppl 1): 31-36.
35. Janinis J, Giannakakis T, Athanasiades A et al. A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group study. Tumori 2000; 86: 37-41.
36. Garcia-del-Muro X, Vadell C, Perez Manga G et al. Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer 1998; 34: 193-195.
37. Matsuoka S, Okamoto S, Watanabe R et al. Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: A prospective randomized study. Int J Hematol 2003; 77: 86-90.
38. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
39. Kurita A, Takashima S, Nakata M et al. Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting in adjuvant chemotherapy, including CDDP against gastric cancer. Gan To Kagaku Ryoho 1997; 24: 49-54.
40. Kleisbauer JP, Garcia-Giron C, Antimi M et al. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs 1998; 9: 387-392.
41. Chevallier B, Marty M, Paillarse JM. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group. Br J Cancer 1994; 70: 1171-1175.
42. Jorgensen M, Victor MA. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Acta Oncol 1996; 35: 159-163.
43. Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004; 22: 725-729.
44. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16: 2937-2942.
45. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
46. de Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 21: 4105-4111.
47. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-2830.
48. Plevy S. Corticosteroid-sparing treatments in patients with Crohn's disease. Am J Gastroenterol 2002; 97: 1607-1617.
49. Rutgeerts PJ. Review article: The limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1515-1525.
50. Vardy JL, Chiew K, Galica J, Tannock IF. Side effects associated with dexamethasone for prophylaxis of delayed emesis after moderately emetogenic therapy. Paper presented at ASCO 2005 (Abstr 8017).
51. Roila F, Warr D, Clark-Snow RA et al. Delayed emesis: Moderately emetogenic chemotherapy. Support Care Cancer 2005; 13: 104-108.
52. Kris MG, Hesketh PJ, Herrstedt J et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005; 13: 85-96.
53. Tonato M, Clark-Snow RA, Osoba D et al. Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 2005; 13: 109-111.
54. European Society for Medical Oncology. ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2005; 16 (Suppl 1): I77-i79.